Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Immunology
IF: 1.404 5-Year IF: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Print: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2018025874
pages 253-261

Does TNF Promote or Restrain Osteoclastogenesis and Inflammatory Bone Resorption?

Baohong Zhao
Arthritis and Tissue Degeneration Program and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, Graduate Program in Biochemistry, Cell and Molecular Biology, Weill Cornell Graduate School of Medical Sciences, and Department of Medicine, Weill Cornell Medical College, 535 E. 70th Street New York, New York 10021

ABSTRACT

Chronic inflammation is one of the most evident and common pathological conditions leading to deregulated osteoclastogenesis and bone remodeling. Tumor necrosis factor (TNF) as a pleiotropic cytokine plays a key role, not only in inflammation, but also in bone erosion in diseases associated with bone loss. TNF can stimulate the proliferation of osteoclast precursors and, in most conditions, act together with other cytokines and growth factors such as receptor activator of nuclear factor (NF)-[kappa]B ligand (RANKL), interleukin-6, and transforming growth factor beta to synergistically promote osteoclast formation and bone resorption in vivo. A longstanding enigma in the field is why TNF alone is not able to induce osteoclast differentiation as effectively as the same superfamily member RANKL, a physiological master osteoclastogenic cytokine. Recent studies have highlighted several lines of evidence showing the intrinsic mechanisms through RBP-J, NF-[kappa]B p100/TNF receptor-associated factor 3, or interferon regulatory factor-8 that restrain TNF-induced osteoclast differentiation and bone resorption. These feedback inhibitory mechanisms driven by TNF shed light into the current paradigm of osteoclastogenesis and would provide novel therapeutic implications on controlling inflammatory bone resorption.


Articles with similar content:

Interleukins in the Control of Osteoclast Differentiation
Critical Reviews™ in Eukaryotic Gene Expression, Vol.8, 1998, issue 2
M. T. Gillespie, E. Romas, T. John Martin
Modulation of the ATP-lnduced Release and Processing of IL-1β in Microglial Cells
Critical Reviews™ in Immunology, Vol.29, 2009, issue 4
Makoto Hashimoto, Yoshifumi Iwamaru, Hiroshi Kitani, Shuei Sugama, Takato Takenouchi
Regulatory Mechanisms Operative in Osteoclasts
Critical Reviews™ in Eukaryotic Gene Expression, Vol.14, 2004, issue 4
Sakamuri V. Reddy
Endothelial Cells as Key Determinants of the Tumor Microenvironment: Interaction with Tumor Cells, Extracellular Matrix and Immune Killer Cells
Critical Reviews™ in Immunology, Vol.30, 2010, issue 6
Muhammad Zaeem Noman, Salem Chouaib, Claudine Kieda, Fathia Mami-Chouaib, Houssem Benlalam, Curzio Ruegg
Regulation of Regulatory T Cells: Role of Dendritic Cells and Toll-Like Receptors
Critical Reviews™ in Immunology, Vol.26, 2006, issue 4
Dieter Kabelitz, Daniela Wesch, Hans-Heinrich Oberg